Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step.
Ontology highlight
ABSTRACT: Hepatic fibrosis and cirrhosis cause strong human suffering and necessitate a monetary burden worldwide. Therefore, there is an urgent need for the development of therapies. Pre-clinical animal models are indispensable in the drug discovery and development of new anti-fibrotic compounds and are immensely valuable for understanding and proofing the mode of their proposed action. In fibrosis research, inbreed mice and rats are by far the most used species for testing drug efficacy. During the last decades, several hundred or even a thousand different drugs that reproducibly evolve beneficial effects on liver health in respective disease models were identified. However, there are only a few compounds (e.g., GR-MD-02, GM-CT-01) that were translated from bench to bedside. In contrast, the large
SUBMITTER: Weiskirchen R
PROVIDER: S-EPMC4703795 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
ACCESS DATA